Fastest Revenue Growth in Health Care
Health Care sector companies ranked by revenue growth. Companies ranked by year-over-year revenue growth based on annual SEC filings.
Health Care SectorTop 50 by Revenue Growth
| # | Company | Revenue Growth |
|---|---|---|
| 1 | XENEXenon Pharmaceuticals Inc. | 763.9% |
| 2 | TALKTalkspace, Inc. | 729.2% |
| 3 | NUVBNuvation Bio Inc. | 699.0% |
| 4 | IBRXImmunityBio, Inc. | 668.3% |
| 5 | CRNXCrinetics Pharmaceuticals, Inc. | 640.7% |
| 6 | SNDXSyndax Pharmaceuticals Inc | 627.8% |
| 7 | SSIISS Innovations International, Inc. | 623.1% |
| 8 | AVDLAVADEL PHARMACEUTICALS PLC | 504.8% |
| 9 | MDGLMADRIGAL PHARMACEUTICALS, INC. | 432.1% |
| 10 | STOKStoke Therapeutics, Inc. | 404.5% |
| 11 | CYTKCytokinetics | 376.6% |
| 12 | IONSIONIS PHARMACEUTICALS INC | 316.5% |
| 13 | SLSSELLAS Life Sciences Group, Inc. | 300.0% |
| 14 | KALVKalVista Pharmaceuticals, Inc. | 294.0% |
| 15 | PRAXPraxis Precision Medicines, Inc. | 249.5% |
| 16 | PHATPhathom Pharmaceuticals, Inc. | 216.9% |
| 17 | URGNUroGen Pharma Ltd. | 186.4% |
| 18 | ABCLAbCellera Biologics Inc. | 160.6% |
| 19 | ANABANAPTYSBIO, INC | 157.0% |
| 20 | TARSTarsus Pharmaceuticals, Inc. | 146.7% |
| 21 | SLNOSOLENO THERAPEUTICS INC | 138.8% |
| 22 | MGTXMeiraGTx Holdings plc | 137.4% |
| 23 | ABUSArbutus Biopharma Corp | 128.2% |
| 24 | BBIOBridgeBio Pharma, Inc. | 126.3% |
| 25 | BEAMBeam Therapeutics Inc. | 120.0% |
| 26 | CNTACentessa Pharmaceuticals plc | 118.9% |
| 27 | KMTSKESTRA MEDICAL TECHNOLOGIES, LTD. | 115.1% |
| 28 | PTCTPTC Therapeutics, Inc. | 114.5% |
| 29 | TVTXTravere Therapeutics, Inc. | 110.5% |
| 30 | RGNXREGENXBIO Inc. | 104.5% |
| 31 | BLLNBillionToOne, Inc. | 100.0% |
| 32 | CAICaris Life Sciences, Inc. | 97.0% |
| 33 | CBLLCeribell, Inc. | 96.9% |
| 34 | ARQTArcutis Biotherapeutics, Inc. | 91.3% |
| 35 | TGTXTG Therapeutics, Inc. | 87.3% |
| 36 | SRRKScholar Rock Holding Corp | 76.4% |
| 37 | RNAAvidity Biosciences, Inc. | 72.1% |
| 38 | TBPHTheravance Biopharma, Inc. | 66.9% |
| 39 | INSMINSMED Inc | 66.7% |
| 40 | AXSMAxsome Therapeutics, Inc. | 65.5% |
| 41 | PVLAPALVELLA THERAPEUTICS, INC. | 65.3% |
| 42 | ALNYALNYLAM PHARMACEUTICALS, INC. | 65.2% |
| 43 | NVAXNOVAVAX INC | 64.7% |
| 44 | RIGLRIGEL PHARMACEUTICALS INC | 64.1% |
| 45 | IOVAIOVANCE BIOTHERAPEUTICS, INC. | 60.6% |
| 46 | LGNDLigand Pharmaceuticals, Inc. | 60.4% |
| 47 | KNSAKiniksa Pharmaceuticals International, plc | 60.1% |
| 48 | HIMSHims & Hers Health | 59.0% |
| 49 | ASTHAstrana Health, Inc. | 56.4% |
| 50 | PRMEPrime Medicine, Inc. | 55.3% |
Understanding Revenue Growth
Revenue growth measures how quickly a company expands its sales. Growth rates are calculated from the two most recent fiscal years. One-time events (acquisitions, divestitures) can significantly impact growth rates.
Rankings are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from this ranking.
Related Rankings
Same Sector
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology